Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Raloxifene treatment has been shown to reduce the risk of vertebral fractures and breast cancer in postmenopausal women. The long-term economic implications of treatment with raloxifene have not yet been investigated. The aim of this study was to assess the cost-effectiveness of treating postmenopausal women in the UK with raloxifene. A previously developed computer simulation model was used to estimate the cost-effectiveness of osteoporotic treatments with extra skeletal benefits. The model was populated with epidemiological data and cost data relevant for a UK female population. Data on the effect of treatment were taken from the Multiple Outcomes of Raloxifene (MORE) study, which recruited women with low bone mineral density or with a prior vertebral fracture. Cost-effectiveness was estimated using Quality Adjusted Life Years (QALYs) and life years gained as primary outcome measures. The cost per QALY gained of treating postmenopausal women without prior vertebral fractures was £18,000, £23,000, £18,000 and £21,000 at 50, 60, 70 and 80 years of age. Corresponding estimates for women with prior vertebral fractures were £10,000, £24,000, £18,000 and £20,000. In relation to threshold values that are recommended in the UK, the analysis suggests that raloxifene is cost-effective in the treatment of postmenopausal women at an increased risk of vertebral fractures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645

    Article  CAS  PubMed  Google Scholar 

  2. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197

    Article  CAS  PubMed  Google Scholar 

  3. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847–857

    Article  CAS  PubMed  Google Scholar 

  4. Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 323:1300–1303

    Article  CAS  PubMed  Google Scholar 

  5. Johannesson M, Hedbrant J and Jonsson B (1991) A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Med Inform (Lond) 16:355–362

    Google Scholar 

  6. Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352–365

    CAS  PubMed  Google Scholar 

  7. Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B (2001) Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12:356–361

    Article  CAS  PubMed  Google Scholar 

  8. Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251–258

    Article  CAS  PubMed  Google Scholar 

  9. Kanis JA, Johnell O, Oden A, De Laet C, Oglesby A, Jonsson B (2002) Intervention thresholds for osteoporosis. Bone 31:26–31

    Article  CAS  PubMed  Google Scholar 

  10. Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120–127

    CAS  PubMed  Google Scholar 

  11. Zethraeus N, Ben Sedrine W, Caulin F, Corcaud S, Gathon HJ, Haim M, Johnell O, Jonsson B, Kanis JA, Tsouderos Y, Reginster JY (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841–857

    Article  CAS  PubMed  Google Scholar 

  12. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125–134

    Article  CAS  PubMed  Google Scholar 

  13. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617

    Article  CAS  PubMed  Google Scholar 

  14. Lothgren M, Zethraeus N (2000) Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9:623–630

    Article  CAS  PubMed  Google Scholar 

  15. Neele SJ, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC (2002) Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30:599–603

    Article  CAS  PubMed  Google Scholar 

  16. Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, Persson I, Ljunghall S (1998) Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 316:1858–1863

    CAS  PubMed  Google Scholar 

  17. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ (1993) The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329:1141–1146

    Article  CAS  PubMed  Google Scholar 

  18. Stevenson JC, Kanis JA, Christiansen C (1992) Bone-density measurement. Lancet 339:370–371

    Article  CAS  Google Scholar 

  19. Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427

    Article  PubMed  Google Scholar 

  20. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11:669–674

    Article  CAS  PubMed  Google Scholar 

  21. Felsenberg D, Silman A, Lunt M, Ambrecht G, Ismail A (2002) Incidence of Vertebral Fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17:716–724

    PubMed  Google Scholar 

  22. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259

    CAS  PubMed  Google Scholar 

  23. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739

    CAS  PubMed  Google Scholar 

  24. Cancer Statistics Registrations—Registrations of cancer diagnosed in 1998, England. Office for National Statistics: London, 2002

  25. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR (1996) Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 276:1404–1408

    Article  CAS  PubMed  Google Scholar 

  26. Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D, Felson DT (1997) Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336:611–617

    Article  CAS  PubMed  Google Scholar 

  27. Kannel W, Wolf P, Garrison R (1987) The Framingham study: an epidemiological investigation of cardiovascular disease. US Department of Commerce National Technical Information Service, Springfield

    Google Scholar 

  28. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM and Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Int Med 158:585–593

    Article  CAS  Google Scholar 

  29. Technology Appraisals Series No. 5: Guidance for Manufacturers and Sponsors (2001) National Institute for Clinical Excellence

  30. Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8:611–617

    Article  CAS  PubMed  Google Scholar 

  31. Kanis J, Brazier J, Stevenson M, Calvert W, Jones ML (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment 6:1–146

    CAS  Google Scholar 

  32. De Laet CE, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 10:66–72

    Article  PubMed  Google Scholar 

  33. Hutton J, Brown R, Borowitz M, Abrams K, Rothman M, Shakespeare A (1996) A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 9 Suppl 2:8–22

    Google Scholar 

  34. Sanderson C, Kubin M (2001) Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs. Health Care Manag Sci 4:269–279

    Article  CAS  PubMed  Google Scholar 

  35. Daly E, Vessey MP, Barlow D, Gray A, McPherson K, Roche M (1996) Hormone replacement therapy in a risk-benefit perspective. Maturitas 23:247–259

    Article  CAS  PubMed  Google Scholar 

  36. Netten A, Rees T, Harrison G (2001) Unit costs of health and Social Care. Personal Social Services Research Unit, University of Kent. www.ukc.ac.uk/PSSRU/

  37. Zethraeus N, Borgström F, Johnell I, Kanis JA, Jönsson B (2002) Costs and quality of life associated with osteoporosis related fractures—results from a Swedish survey. Working Paper Series in Economics and Finance, 512

  38. Lundberg L (1999) Health-related quality of life in Sweden. Faculty of Pharmacy, Uppsala University

  39. Kanis J, Johnell O, Oden A, Borgström F, Zethraeus N, Laet CD, Jönsson B (2004) The risk and burden of vertebral fracture in Sweden. Osteoporosis Int 15:20–26

    Article  CAS  Google Scholar 

  40. Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316:736–741

    CAS  PubMed  Google Scholar 

  41. Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314

    PubMed  Google Scholar 

  42. Iglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. Q J Med 95:305–311

    Article  CAS  Google Scholar 

  43. Johannesson M (1995) The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics 7:242–250

    CAS  PubMed  Google Scholar 

  44. Interim Life Tables (2002) Government Actuary’s Department

  45. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561

    Article  CAS  PubMed  Google Scholar 

  46. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882

    Article  CAS  PubMed  Google Scholar 

  47. Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001–1005

    CAS  PubMed  Google Scholar 

  48. Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, Laet CD, Jönsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42

    Article  CAS  PubMed  Google Scholar 

  49. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ 3rd (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Int Med 160:761–768

    Article  CAS  Google Scholar 

  50. Kearon C (2003) Natural history of venous thromboembolism. Circulation 107:122–130

    Article  Google Scholar 

  51. Frost ML, Blake GM, Fogelman I (2001) Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis. J Bone Miner Res 16:406–416

    CAS  PubMed  Google Scholar 

  52. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585–590

    Article  CAS  PubMed  Google Scholar 

  53. Kanis J, Johnell O, Black D, Downs R, Sarkar S, Feurst T, Secrest R, Pavo I (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women defined by total hip bone mineral density. Bone 33:293–300

    Article  CAS  PubMed  Google Scholar 

  54. Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291–297

    Article  CAS  PubMed  Google Scholar 

  55. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109–3115

    Article  CAS  PubMed  Google Scholar 

  56. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term prevention effects on bone mass and osteoporotic fractures: the PERF study. Bone 34:728–735

    Article  CAS  PubMed  Google Scholar 

  57. Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J, McCloskey EV (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18:1254–1260

    PubMed  Google Scholar 

  58. National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporos Int 8 (Suppl 4):1–88

    Article  Google Scholar 

  59. Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13:768–776

    Article  CAS  PubMed  Google Scholar 

  60. Inglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. Q J Med 95:305–311

    Article  CAS  Google Scholar 

  61. Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int (in press)

  62. Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost-effectiveness of raloxifene in Sweden. An economic evaluation based on the MORE study. Pharmacoeconomics (in press)

Download references

Acknowledgements

We are grateful to Eli Lilly and Co. for their unrestricted support of this work.

Author information

Authors and Affiliations

  1. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK

    J. A. Kanis

  2. Stockholm Health Economics, Stockholm, Sweden

    F. Borgström

  3. Department of Orthopaedics, Malmo General Hospital, Malmo, Sweden

    O. Johnell

  4. Consulting Statistician, Gothenburg, Sweden

    A. Oden

  5. Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, UK

    D. Sykes

  6. Department of Economics, Stockholm School of Economics, Stockholm, Sweden

    B. Jönsson

  7. Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK

    J. A. Kanis

Authors
  1. J. A. Kanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Borgström
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. Johnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Oden
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Sykes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Jönsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. A. Kanis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanis, J.A., Borgström, F., Johnell, O. et al. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16, 15–25 (2005). https://doi.org/10.1007/s00198-004-1688-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-004-1688-0

Keywords

Search

Navigation